CHOC’s study published in the Pediatrics journal finds that though COVID-19 infections in newborns are rare, they may cause severe disease.
The Fragile X Clinic at CHOC will be devoted to the diagnosis, treatment, and study of the rare genetic condition of Fragile X syndrome.
CHOC selected as West Coast site for gene therapy clinical trial for patients 8 years and older with Glycogen Storage Disease type 1a.
CHOC’s pediatric colorectal program makes a significant impact on children with treatments and tools for correcting colorectal issues.
New CHOC study integrating mental health into primary care seeks patients to receive cognitive therapy and/or medication.
The NICU Bridge Clinic Program at CHOC offers follow-up care for high-risk infants, reducing the length of stays and hospital readmissions.